Author(s)

Alina S. Fedorova^1*, Maria V. Stegantseva², Nina V. Minakovskaya³, Olga V. Aleinikova¹

¹Clinical Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus.
²Laboratory of Genetic Biotechnology, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus.
³Department of Bone Marrow Transplantation, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus.

Minimal residual disease (MRD) appears to have a strong negative predictive value for disease recurrence in children with anaplastic large cell lymphoma (ALCL). Brentuximab vedotin (BV) can be a therapeutic option for MRD-positive patients to achieve molecular remission and to decrease risk of subsequent relapse. We here report a 4-year-old child with ALCL progression during relapse treatment who received BV as a bridging therapy before haploidentical hematopoietic stem-cell transplantation, and as a maintenance therapy post-transplant alone or combined with simultaneous low dose donor-lymphocyte infusions. MRD monitoring showed a complete molecular response and reflected both BV efficiency and graft-versus-lymphoma effect.

Anaplastic Large Cell Lymphoma, Relapse, Brentuximab Vedotin, Donor Lymphocyte Infusion, Minimal Residual Disease

Fedorova, A. , Stegantseva, M. , Minakovskaya, N. and Aleinikova, O. (2017) Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma. Journal of Cancer Therapy, 8, 683-690. doi: 10.4236/jct.2017.88059.